Technology
Health
Biotechnology

Stemline

$14.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Stemline and other stocks, options, ETFs, and crypto commission-free!

About

Stemline Therapeutics, Inc. Common Stock, also called Stemline, is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Read More Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Employees
92
Headquarters
New York, New York
Founded
2003
Market Cap
634.03M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
422.50K
High Today
$15.06
Low Today
$14.46
Open Price
$14.51
Volume
167.48K
52 Week High
$20.55
52 Week Low
$7.82

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Pharmaceutical
2013 IPO

News

BenzingaMay 13

Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock

Stemline Therapeutics Inc (NASDAQ: STML) reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago.

23
Seeking AlphaMay 10

Stemline Therapeutics' CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript

Stemline Therapeutics, Inc (NASDAQ:STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Ivan Bergstein – Chief Executive Officer Robert Francomano – Senior Vice President Global Head of Commercial David Gionco – Chief Accounting Officer Conference Call Participants Jessica Fye – JP Morgan Boris Peaker – Cowen Matt Kaplan – Ladenburg Thalmann Ram Selvaraju – Wainwright Joe Catanzaro – Piper Jaffray Jotin Marango – Roth Capital ...

46
Yahoo FinanceMay 10

Stemline Therapeutics Reports Q1 Loss, Tops Revenue Estimates

Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

40

Earnings

-$0.93
-$0.82
-$0.72
-$0.61
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.63 per share
Actual
-$0.73 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.